WO2015057403A3 - Compositions and methods for treatment of inflammatory bowel disease - Google Patents

Compositions and methods for treatment of inflammatory bowel disease Download PDF

Info

Publication number
WO2015057403A3
WO2015057403A3 PCT/US2014/058981 US2014058981W WO2015057403A3 WO 2015057403 A3 WO2015057403 A3 WO 2015057403A3 US 2014058981 W US2014058981 W US 2014058981W WO 2015057403 A3 WO2015057403 A3 WO 2015057403A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
bowel disease
treatment
compositions
methods
Prior art date
Application number
PCT/US2014/058981
Other languages
French (fr)
Other versions
WO2015057403A2 (en
Inventor
Richard Franklin
Original Assignee
Tarix Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd. filed Critical Tarix Pharmaceuticals Ltd.
Publication of WO2015057403A2 publication Critical patent/WO2015057403A2/en
Publication of WO2015057403A3 publication Critical patent/WO2015057403A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides improved methods for treating inflammatory bowel disease in all of its forms. The present invention is based, in part, on the surprising discovery that treatment with angiotensin peptide significantly improves several of the symptoms observed in a mouse model of inflammatory bowel disease including weight loss and disease activity index. This is particularly unexpected due to the suggestions that ACE-2 inhibitors are of utility in treating these diseases. The beneficial use of ACE2 inhibitors in treating inflammatory conditions would lead one to believe that they would not be of benefit, or may even be harmful in such a condition.
PCT/US2014/058981 2013-10-17 2014-10-03 Compositions and methods for treatment of inflammatory bowel disease WO2015057403A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361892307P 2013-10-17 2013-10-17
US61/892,307 2013-10-17

Publications (2)

Publication Number Publication Date
WO2015057403A2 WO2015057403A2 (en) 2015-04-23
WO2015057403A3 true WO2015057403A3 (en) 2015-11-05

Family

ID=52828840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/058981 WO2015057403A2 (en) 2013-10-17 2014-10-03 Compositions and methods for treatment of inflammatory bowel disease

Country Status (1)

Country Link
WO (1) WO2015057403A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987403B2 (en) 2017-03-10 2021-04-27 University Of Southern California Cyclodextrin-Nle3-A(1-7) compositions and their use
CN108763863A (en) * 2018-05-30 2018-11-06 西北民族大学 The quantitative structure activity relationship model of ace inhibitory peptide and its application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151009A1 (en) * 2000-02-24 2002-10-17 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
US20040121429A9 (en) * 2001-06-04 2004-06-24 Parry Tom J. Methods and compositions for modulating ACE-2 activity
US20050266532A1 (en) * 2000-04-12 2005-12-01 Human Genome Sciences, Inc. Albumin fusion proteins
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151009A1 (en) * 2000-02-24 2002-10-17 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
US20050266532A1 (en) * 2000-04-12 2005-12-01 Human Genome Sciences, Inc. Albumin fusion proteins
US20090285816A9 (en) * 2000-04-12 2009-11-19 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20040121429A9 (en) * 2001-06-04 2004-06-24 Parry Tom J. Methods and compositions for modulating ACE-2 activity
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development

Also Published As

Publication number Publication date
WO2015057403A2 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
BR112015012312A2 (en) method of treatment, risk reduction, prevention or alleviation of a condition or lung disease in a subject; method of reducing or suppressing lung inflammation in a subject; and method of promoting pulmonary repair in a subject
EA201201648A1 (en) SGC STIMULATORS
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2012045089A3 (en) Methods for the treatment of allergic diseases
WO2011083150A3 (en) Obesity small molecules
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2012050874A3 (en) Targeting heme for the treatment of immune mediated inflammatory diseases
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
IN2012DN00624A (en)
WO2012044090A3 (en) Novel aminoquinazoline compound having a protein-kinase inhibiting action
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2014210037A3 (en) A composition of mesenchymal stem cells
WO2012097272A8 (en) Stable hydrogel compositions including additives
EA201491532A1 (en) PHARMACEUTICAL COMPOSITIONS FOR USE IN COMPLEX THERAPY
WO2015080980A3 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
PL2892556T3 (en) Compositions and methods relating to the treatment of diseases
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
EP2585067A4 (en) Compound for the treatment of enteroviruses
WO2012018866A3 (en) Methods and compositions for the diagnosis and treatment of breast cancer
WO2015057403A3 (en) Compositions and methods for treatment of inflammatory bowel disease
WO2014130313A3 (en) Methods and compositions relating to the treatment of cancer
UA111520C2 (en) [1,2,4]triazolopyridine compounds and used thereof as phosphodiesterase inhibitors
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
EP2582392A4 (en) Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14854783

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14854783

Country of ref document: EP

Kind code of ref document: A2